NCT03768609View on ClinicalTrials.gov

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

March 6, 2019

Study Completion Date

March 12, 2019

Conditions
Healthy
Interventions
DRUG

Pimodivir

Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.

DRUG

Cyclosporine

Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY

NCT03768609 - A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults | Biotech Hunter | Biotech Hunter